Gene · 9966
Papers2,280
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,280
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Regulatory mechanisms of Th9 cell differentiation. | Front Immunol | 2025 | 40948790 | PubTator, text mining | PubMed |
| Genetic background of neurological disorders with basal ganglia calcification. | J Neurol | 2025 | 40947452 | PubTator, text mining | PubMed |
| Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy. | Korean J Clin Oncol | 2025 | 40916400 | PubTator, text mining | PubMed |
| Network toxicological insights into DEHP exposure and thyroid cancer development and progression. | Front Oncol | 2025 | 40900788 | PubTator, text mining | PubMed |
| L009 peptide as a novel antiangiogenic agent for corneal neovascularization via regulation of the TNFSF15-VEGF axis. | Ocul Surf | 2025 | 40882778 | PubTator, text mining | PubMed |
| Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression. | Discov Oncol | 2025 | 40853435 | PubTator, text mining | PubMed |
| Investigating Liquid-Liquid Phase Separation in Lung Adenocarcinoma to Improve Prognostic Accuracy and Treatment Efficacy. | J Cell Mol Med | 2025 | 40845073 | PubTator, text mining | PubMed |
| FEN1 plays a key role in the transition from HSIL to CSCC. | Sci Rep | 2025 | 40820150 | PubTator, text mining | PubMed |
| Potential Influence of TNFSF15 Genetic Variants and Expression Levels on Disease Progression in Patients With Hepatocellular Carcinoma. | Mol Carcinog | 2025 | 40762626 | PubTator, text mining | PubMed |
| Identification of novel molecular subtypes and construction of a prognostic signature via multi-omics analysis and machine learning in lung adenocarcinoma. | Front Oncol | 2025 | 40761262 | PubTator, text mining | PubMed |
| Characterization of novel anoikis-related genes as prognostic biomarkers and key determinants of the immune microenvironment in esophageal cancer. | Front Immunol | 2025 | 40746552 | PubTator, text mining | PubMed |
| HCAR3 May Mediate Autism Symptoms: Evidence From RNA-Sequencing of Peripheral Blood Mononuclear Cells. | Psychiatry Investig | 2025 | 40738169 | PubTator, text mining | PubMed |
| Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial. | Lancet Gastroenterol Hepatol | 2025 | 40706613 | PubTator, text mining | PubMed |
| Diverticulitis: A Review. | JAMA | 2025 | 40705318 | PubTator, text mining | PubMed |
| Humoral determinants of checkpoint immunotherapy. | Nature | 2025 | 40702172 | PubTator, text mining | PubMed |
A nomogram model based on tumor necrosis factor-like ligand 1A(TL1A) and death receptor-3(DR3) promoter methylation for predicting 90-day prognosis in patients with HBV-associated acute-on-chronic liver failure. | Front Mol Biosci | 2025 | 40678004 | PubTator, text mining | PubMed |
| Psychiatric manifestations in a patient with a pathogenic variant in the MT-TL1 gene associated with MELAS. | BMJ Case Rep | 2025 | 40562545 | PubTator, text mining | PubMed |
| Targeting programmed cell death with natural products: a potential therapeutic strategy for diminished ovarian reserve and fertility preservation. | Front Pharmacol | 2025 | 40510420 | PubTator, text mining | PubMed |
| TL1A as a Target in Inflammatory Bowel Disease: Exploring Mechanisms and Therapeutic Potential. | Int J Mol Sci | 2025 | 40507829 | PubTator, text mining | PubMed |
| TiO2/WO3 nanoarrays photodetector and liposomes equipped with electron donor-mediated signal amplification for immunoassay applications. | Biosens Bioelectron | 2025 | 40499458 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9966/papers?page=5